Why the study?
Does dronedarone improve safety but reduce efficacy compared to amiodarone in patients with paroxysmal or persistent atrial fibrillation or atrial flutter?
Does dronedarone improve safety but reduce efficacy compared to amiodarone in patients with paroxysmal or persistent atrial fibrillation or atrial flutter?
Dronedarone is a safer but less effective alternative to amiodarone, indicated to reduce hospitalization in patients with atrial fibrillation or flutter.
May support dronedarone consideration to minimize toxicity in select AF patients; leaves open optimal selection and long-term outcomes.
Dronedarone (Multaq), an analogue of amiodarone (Cordarone), was designed to cause fewer adverse effects than the parent compound. Studies have indeed shown dronedarone to be safer than amiodarone, but less effective. Its official indication is to reduce the risk of hospitalization in patients with paroxysmal or persistent atrial fibrillation or atrial flutter and other cardiovascular risk factors, reflecting the parameters of its effectiveness in clinical trials.
No takes yet. Share an insight, caveat, or question.
Penugonda et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: